Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Canada’s most-awarded
newsroom for a reason
Stay informed for a
lot less, cancel anytime
“Exemplary reporting on
COVID-19” – Herman L
$1.99
per week
for 24 weeks
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Employees pack boxes containing vials of AstraZeneca's COVID-19 vaccine at Serum Institute of India in Pune, India, on Jan. 21, 2021.

Rafiq Maqbool/The Associated Press

The Biden administration is refusing to allow AstraZeneca to export tens of millions of unused doses of its COVID-19 vaccine, despite a plea from the Canadian government to import the shots in a bid to bolster Ottawa’s lagging inoculation drive.

The U.S. has not yet authorized the British-Swedish drug-maker’s vaccine for use, but is nonetheless insisting that all shots the company produces in the country be kept off the export market. Canada and the European Union, meanwhile, have approved the vaccine, but cannot access the supply in the U.S.

Much of AstraZeneca’s American stockpile is sitting idle at a plant near Cincinnati, less than four hours’ drive from the Canadian border, at a time when Canada’s vaccine shortages have caused it to fall well behind the U.S. in administering doses. If AstraZeneca were allowed to export these shots, it could more than fill Canada’s entire contract with the drug-maker – 20 million doses – before the end of this month.

Story continues below advertisement

A Canadian official told The Globe and Mail that Public Services and Procurement Minister Anita Anand has raised the issue with the U.S. government. The Globe agreed not to identify the official in order to learn the details of confidential bilateral discussions.

Tracking Canada’s COVID-19 vaccine rollout plans: A continuing guide

Coronavirus tracker: How many COVID-19 cases are there in Canada and worldwide? The latest maps and charts

Jeff Zients, the White House coronavirus response co-ordinator, said Friday that the U.S. is hoarding the doses so it can be ready to roll them out to Americans as soon as the Food and Drug Administration approves the vaccine.

“We have a small inventory of AstraZeneca so that, if approved, we can get that inventory out to the American people as quickly as possible,” he said in a briefing.

White House press secretary Jen Psaki said President Joe Biden wants to ensure all Americans are inoculated before allowing U.S.-made doses to be exported.

“At this time, there have been requests from around the world, of course, from a number of countries who have requested doses from the United States. And we have not provided doses from the U.S. government to anyone,” she told reporters.

The U.S. has also refused to allow Pfizer and Moderna to export COVID-19 vaccines to Canada from their plants in the U.S. This left Ottawa to rely on plants in Europe, which slowed production to a trickle in February as they retooled to meet the demand.

In a statement to The Globe, AstraZeneca said it would produce roughly 30 million doses in the U.S. by the end of March and another 20 million by the end of April.

Story continues below advertisement

According to AstraZeneca’s contract with the U.S. government, signed last May, all doses made in the U.S. are owned by the U.S. government. The company confirmed that this means the Biden administration must agree for any doses to be exported.

The drug-maker said it had encouraged the U.S. government to “give thoughtful consideration” to requests from other countries to buy the supply currently sitting unused.

Prime Minister Justin Trudeau would not say Friday whether he had asked the White House to let Ottawa import the shots. “Over the past number of months, we’ve had lots of great engagements with the American administration on COVID-19,” he told a press conference in Ottawa.

Ms. Anand said she still expected to receive the AstraZeneca doses from the U.S. Earlier this week, she told reporters that she believed AstraZeneca would be able to fulfill its contract with Canada. The deal calls for the shots to be delivered between April and September, giving the White House several weeks to reverse its current protectionist decision.

“We have no reason to doubt that they will be coming into this country,” she said.

Mr. Biden said earlier this week that, once his country has enough vaccine in hand to inoculate all Americans, he would look at exporting shots for other countries. This raises the possibility that the White House could allow AstraZeneca to start supplying Canada from the U.S. if the American vaccine supply continues to rise significantly.

Story continues below advertisement

“If we have a surplus, we’re going to share it with the rest of the world,” he said.

Even if AstraZeneca fulfills its contract with Canada, however, this will not see all 20 million shots delivered until the fall. Meanwhile, Ottawa could use the idle shots sitting in Ohio right now.

According to calculations by a team at the University of Oxford, fewer than 2 per cent of Canadians are currently vaccinated against COVID-19, compared with more than 10 per cent of Americans.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies